
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
It's morning on an unseasonably warm Tuesday in February. As you walk across campus from grand rounds, a page from the pediatric emergency department signals that a patient is waiting to be admitted. Off you go!






